The rise of Ebola cases in parts of the Democratic Republic of the Congo and Uganda has renewed attention on how travelers and clinicians should respond. This guide lays out clear, actionable steps for people returning from affected regions, plus essential clinical principles for health professionals evaluating potential cases. It combines traveler-focused monitoring with hospital-level assessment and treatment priorities so both audiences know what to expect and how to act.
Information is presented in practical terms: how long to watch symptoms, which signs matter most, when to notify public health authorities, and what treatments and infection control measures are currently available. Throughout, Ebola and related technical terms are highlighted so readers can quickly find the most important points.
For travelers: monitoring and immediate actions
If you have recently been in the Democratic Republic of the Congo, Kampala in Uganda, or neighboring countries with known transmission, it is important to monitor your health for 21 days after leaving the area. The 21-day period reflects the upper bound of the incubation window for orthoebolaviruses. During this time, check your temperature daily and any time you feel unwell. If you did not visit a designated area of concern but did travel within the same country, you should still be alert and take your temperature when symptoms appear.
Symptoms to watch for
The most common early signs include fever (100.4°F/38°C or higher), headache, and muscle aches. Gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain can follow. A rash, persistent weakness, sore throat, or unexplained bleeding or bruising are also important to note; bleeding tends to occur later in the clinical course. If you experience any of these, isolate yourself from others and seek medical advice.
When and how to seek help
Contact your local public health department immediately if you develop symptoms during the 21-day period. Public health teams typically follow up with travelers and will advise on testing, isolation needs, and the most appropriate healthcare facility. If urgent care is required and you cannot reach public health officials right away, call ahead to the emergency department or your healthcare provider and tell them about your recent travel so they can prepare and take appropriate precautions.
For healthcare providers: evaluation and infection control
Clinicians assessing a patient with recent travel to an affected region should include Ebola in the differential diagnosis when clinical presentation and epidemiologic history align. However, most returning travelers who are sick will have more common infections such as malaria or bacterial illnesses. Do not delay routine diagnostic testing and treatment for these more likely conditions while evaluating for a viral hemorrhagic fever.
Immediate steps in the clinical setting
If Ebola is suspected, place the patient in a single room and apply proper infection prevention and control measures without delay. Healthcare workers must wear appropriate personal protective equipment (PPE) and use dedicated equipment to prevent direct or indirect transmission. Notify the jurisdictional health department right away and consult with public health officials and the CDC’s specialized teams when needed to determine testing and next steps.
Testing and coordination
Clinical teams should coordinate assessment with public health so that laboratory testing, patient transport, and isolation are handled safely. Use established jurisdictional protocols for reporting and for activating on-call epidemiologic support when necessary. Early coordination ensures safer care, appropriate diagnostic choices, and faster determination of the true cause of illness.
Treatment principles and special considerations
Treatment for Ebola focuses first on high-quality supportive care: aggressive fluid and electrolyte management, hemodynamic support with vasopressors when indicated, oxygenation support, pain control, nutritional care, and treatment of secondary bacterial infections. Supportive measures have a strong impact on survival when started early.
Therapeutics and vaccines
For Ebola caused by Ebola virus (Zaire species), there are FDA-approved monoclonal antibody therapies that have shown improved survival in clinical trials. These include combination and single-antibody regimens that target the viral glycoprotein to limit replication. A licensed vaccine is available for prevention against this species as well. However, no FDA-approved vaccines or therapeutics currently exist for other human-pathogenic orthoebolaviruses such as Sudan virus, Bundibugyo virus, or Taï Forest virus; investigational options remain under study.
Special populations
Certain groups require tailored approaches: pregnant women and neonates need obstetric and neonatal planning that balances maternal and neonatal risks and provider safety; patients on long-term renal replacement therapy need protocols for safe dialysis; and survivors may face chronic complications and viral persistence in immune-privileged sites. Consult public health authorities and specialty teams for management advice in these situations.
Whether you are a traveler or a clinician, prompt recognition, careful monitoring, and close coordination with public health are the cornerstones of preventing further spread and optimizing patient outcomes. Maintain vigilance during the 21-day observation window, follow public health instructions, and use recommended infection control and clinical practices when evaluating and treating suspected cases.
